Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave Acetate in Open-Angle Glaucoma
NCT00705770Phase 3Withdrawn
- Sponsor
- Alcon Inc.
- Start
- May 2008
- Primary completion
- Jul 2008
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of anecortave in open-angle glaucoma (OAG) (4 arms), sponsored by Alcon Inc. Primary endpoint: Mean Intraocular Pressure at 6 months. Planned start May 2008; status: withdrawn.
02
Drugs
anecortave
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT00705770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705770.